

## Anti-PCSK9 Antibody (Recaticimab)

### Introduction

Recaticimab (SHR-1209) is a PCSK9 antibody. Recaticimab can be used with PCSK9. Recaticimab binds to and mediates its degradation, increasing the expression of low-density lipoprotein (LDL) on the surface of hepatocytes. Recaticimab reduces plasma LDL receptor levels, reducing plasma LDL. Recaticimab can be used in the study of hypercholesterolemia.

### Product parameters

Alternative Names	SHR 1209, SHR-1209
Target Accession	Q8NBP7
Target	PCSK9
CAS number	2361290-85-7
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	-
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



**APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

